ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1803

General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia

Regaip Elezi1, Gulsum Emel Pamuk2, Muhammet Maden2, Mehmet Ali Balci1,3 and Omer Nuri Pamuk1, 1Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 2Hematology, Trakya University Medical Faculty, Edirne, Turkey, 3Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Anemia, autoimmunity and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Anemia in systemic lupus erythematosus (SLE) might have various etiologies; however, autoimmune hemolytic anemia (AIHA) is the characteristic hematologic feature. AIHA might be primary or have other etiologies as well. We evaluated the demographic, clinical features and prognosis of SLE patients with AIHA. In addition, their features and prognosis were compared to AIHA patients who were admitted to the Hematology Department of our institution.

Methods:  Data about SLE patients with AIHA were obtained from patients’ medical records. The diagnosis of SLE was based on 1997 revised ACR criteria. SLE patients with and without AIHA were compared to each other. In addition, medical records of patients with AIHA being followed up at the Hematology Department were screened for their clinical features and outcome.

Results: We included 333 SLE patients (307 females, 26 males, mean age: 37.7±12.4 years). AIHA was diagnosed in 20 patients (6%). Male SLE patients had more frequent AIHA than females (15.4% vs. 4.6%, p=0.04). Coombs test positivity was present in 60 patients (18%). Coombs positivity tended to be more frequent in male SLE patients (30.8% vs. 16.9%, p=0.1). SLE patients with AIHA had more frequent active disease (SLEDAI>4) (75% vs. 42.2%, p=0.006), accompanying thrombocytopenia (45% vs. 14.4%, p=0.003), renal involvement (50% vs. 28.5%, p=0.05), anti-dsDNA positivity (65% vs. 47.6%, p=0.12) and hypocomplementemia (70% vs. 33%, p=0.002). Contrarily, photosensitivity (40% vs. 69.5%, p=0.01) and arthritis (40% vs. 78.7%, p=0.001) were significantly less frequent in SLE patients with AIHA. Fortytwo patients (11.5%) had Coombs positivity without AIHA. Coombs (+) SLE patients had less frequent photosensitivity (53.3% vs. 71.1%, p=0.01); however, more frequent pleural involvement (25% vs. 14.3%, p=0.04), leucopenia (55% vs. 37.3%, p=0.01), lymphopenia (75% vs. 59.8%, p=0.03), anti-dsDNA positivity (70% vs. 44%, p=0.001), anti-ribozomal P positivity (11.9% vs. 4.5%, p=0.05), renal involvement (51.7% vs. 24.7%, p=0.001) and hypocomplementemia (67.3% vs. 27.7%,p=0.001). Two patients presented with AIHA during pregnancy. Survival of SLE patients with and without AIHA were not found to be different. When clinical features of fortyone AIHA patients (27 female, 14 male, mean age: 61.1±18 vs 35.4±10.5) diagnosed at the Hematology Department were compared to SLE patients with AIHA, the former group was significantly older (p<0.001). Being female (85% vs. 65.9%, p=0.1) and relapses (20% vs. 9.8%, p=0.2) tended to be more frequent in the SLE group. SLE patients with AIHA and other AIHAs had similar survival.

Conclusion:  AIHA was diagnosed in 6% of our SLE patients. AIHA was more frequent in males and seemed to be associated with active disease, renal involvement, and anti-dsDNA positivity. SLE patients with AIHA were significantly younger than AIHA patients being follwed up at the Hematology Department.


Disclosure: R. Elezi, None; G. E. Pamuk, None; M. Maden, None; M. A. Balci, None; O. N. Pamuk, None.

To cite this abstract in AMA style:

Elezi R, Pamuk GE, Maden M, Balci MA, Pamuk ON. General Features of SLE Patients Presenting with Autoimmune Hemolytic Anemia [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/general-features-of-sle-patients-presenting-with-autoimmune-hemolytic-anemia/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/general-features-of-sle-patients-presenting-with-autoimmune-hemolytic-anemia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology